Min-Kyu Park (MinKyu Park, Min Kyu Park)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Computed Tomography

Glycemic Control

Top Venues

Translational and clinical pharmacology

Expert opinion on biological therapy

Diabetes, obesity & metabolism

Clinical interventions in aging

This page only lists publications with an associated author ORCID identifier.

Publications

Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy 24 (7) (2024)
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy 24 (7) (2024)
Sae Im Jeong, Mu Seong Ban, Jun Gi Hwang, Min-Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae-Young Chung
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes. Diabetes, obesity & metabolism (2024)
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy 24 (7) (2024)
Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin, Min-Kyu Park, Jun Gi Hwang, Seol Ju Moon, Min Gul Kim, Edward C Keystone, Josef S Smolen, SungHyun Kim, YunJu Bae, DaBee Jeon, JiYoung Jang, GoEun Yang, JiHun Bae, JaeYong Lee, Gerd R Burmester
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert opinion on biological therapy (2024)
Sae Im Jeong, Mu Seong Ban, Jun Gi Hwang, Min-Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae-Young Chung
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes. Diabetes, obesity & metabolism 26 (7) (2024)
Se Rin Park, Jun Gi Hwang, Sae Im Jeong, Young-Sim Choi, Hyo Jin Min, Hye Yun Kim, Bong-Hoi Choi, Min-Kyu Park
Comparison of the pharmacokinetic characteristics and bioequivalence between two nanosuspension formulations of megestrol acetate in healthy Korean male subjects. Translational and clinical pharmacology 32 (1) (2024)
Se Rin Park, Jun Gi Hwang, Sae Im Jeong, Young-Sim Choi, Hyo Jin Min, Hye Yun Kim, Bong-Hoi Choi, Min-Kyu Park
Comparison of the pharmacokinetic characteristics and bioequivalence between two nanosuspension formulations of megestrol acetate in healthy Korean male subjects. Translational and clinical pharmacology 32 (1) (2024)
Jun Gi Hwang, Sae Im Jeong, Yu-Kyong Kim, Yujin Lee, Sang Chun Ji, Seung Hwan Lee, Min-Kyu Park
Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Translational and clinical pharmacology 30 (4) (2022)
Jun Gi Hwang, Sae Im Jeong, Yu-Kyong Kim, Yujin Lee, Sang Chun Ji, Seung Hwan Lee, Min-Kyu Park
Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Translational and clinical pharmacology 30 (4) (2022)
Yu-Kyong Kim, Jun Gi Hwang, Min-Kyu Park
No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects. Drug design, development and therapy 15 (2021)
Saerom Kang, Sook Joung Lee, Min-Kyu Park, Eunseok Choi, Sangjee Lee
The therapeutic effect and complications of oro-esophageal tube training in stroke patients. Clinical interventions in aging 14 (2019)